New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study - PACE-CME

New class of lipidlowering medication shows lasting LDLc lowering in dosefinding study

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Icosapent ethyl in post-CABG patients with diabetes
Icosapent ethyl in post-CABG patients with diabetes
Hyperlipidemia
Icosapent ethyl in post-CABG patients with diabetes
- Subodh Verma, MD, PhD
Phase 3 study results of plozasiran in patients with FCS
Phase 3 study results of plozasiran in patients with FCS
Hyperlipidemia
Phase 3 study results of plozasiran in patients with FCS
- Gerald F. Watts, DSc, DM, PhD
New ESC Guidelines for CCS and PAAD
New ESC Guidelines for CCS and PAAD
ESC Congress 2024
New ESC Guidelines for CCS and PAAD
- Pierre Sabouret, MD, PhD
Intensive and early lowering of atherogenic lipids after MI
Intensive and early lowering of atherogenic lipids after MI
ESC Congress 2024
Intensive and early lowering of atherogenic lipids after MI
- Jessica Schubert, MD